Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
34
LAB Quote, Financials, Valuation and Earnings
Last price:
$1.29
Seasonality move
:
6.15%
Day range:
$1.24 - $1.33
52-week range:
$0.92 - $2.14
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.74x
P/B ratio:
1.22x
Volume:
2.6M
Avg. volume:
1.9M
1-year change:
-28.25%
Market cap:
$488.4M
Revenue:
$174.4M
EPS (TTM):
-$0.34
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
LAB
Standard BioTools, Inc.
|
$18.5M | -$0.03 | -60.4% | -72.53% | $1.65 |
|
ADGM
Adagio Medical Holdings, Inc.
|
-- | -$0.31 | -100% | -91.79% | $4.00 |
|
INBS
Intelligent Bio Solutions, Inc.
|
$1.4M | -- | 160.36% | -- | -- |
|
LNSR
LENSAR, Inc.
|
$20.5M | -$0.09 | 30.98% | -90.51% | $15.00 |
|
MOVE
Movano, Inc.
|
$3.4M | -$7.10 | 76.06% | -41.21% | $30.00 |
|
NPCE
NeuroPace, Inc.
|
$24.4M | -$0.19 | 13.81% | -5.76% | $19.25 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
LAB
Standard BioTools, Inc.
|
$1.27 | $1.65 | $488.4M | -- | $0.00 | 0% | 3.74x |
|
ADGM
Adagio Medical Holdings, Inc.
|
$0.99 | $4.00 | $21M | 218.00x | $0.00 | 0% | 110.91x |
|
INBS
Intelligent Bio Solutions, Inc.
|
$10.70 | -- | $10.3M | -- | $0.00 | 0% | 21.27x |
|
LNSR
LENSAR, Inc.
|
$11.45 | $15.00 | $136.8M | -- | $0.00 | 0% | 2.29x |
|
MOVE
Movano, Inc.
|
$7.78 | $30.00 | $6.5M | -- | $0.00 | 0% | 11.77x |
|
NPCE
NeuroPace, Inc.
|
$16.39 | $19.25 | $545.9M | -- | $0.00 | 0% | 5.50x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
LAB
Standard BioTools, Inc.
|
6.41% | 0.680 | 5.49% | 1.93x |
|
ADGM
Adagio Medical Holdings, Inc.
|
106.35% | 0.022 | 73.62% | 0.48x |
|
INBS
Intelligent Bio Solutions, Inc.
|
35.02% | 2.237 | 21.48% | 0.47x |
|
LNSR
LENSAR, Inc.
|
-31.16% | -0.941 | 1.79% | 0.65x |
|
MOVE
Movano, Inc.
|
212.35% | 3.110 | 67.05% | 0.29x |
|
NPCE
NeuroPace, Inc.
|
79.36% | 0.372 | 20.74% | 3.82x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
LAB
Standard BioTools, Inc.
|
$9.5M | -$23.5M | -22.34% | -24.44% | -120.02% | -$23.1M |
|
ADGM
Adagio Medical Holdings, Inc.
|
-$531K | -$5.7M | -193.23% | -340.49% | -- | -$3.5M |
|
INBS
Intelligent Bio Solutions, Inc.
|
$214.9K | -$2.9M | -213.68% | -255.54% | -263.64% | -$2.9M |
|
LNSR
LENSAR, Inc.
|
$5.8M | -$7.6M | -684.94% | -1013.45% | -52.95% | -$3.5M |
|
MOVE
Movano, Inc.
|
-$200K | -$2.6M | -337.24% | -410.28% | -3238.75% | -$1.6M |
|
NPCE
NeuroPace, Inc.
|
$21.2M | -$2.6M | -27.09% | -149.8% | -9.51% | -$2M |
Standard BioTools, Inc. vs. Competitors
-
Which has Higher Returns LAB or ADGM?
Adagio Medical Holdings, Inc. has a net margin of -162.05% compared to Standard BioTools, Inc.'s net margin of --. Standard BioTools, Inc.'s return on equity of -24.44% beat Adagio Medical Holdings, Inc.'s return on equity of -340.49%.
Company Gross Margin Earnings Per Share Invested Capital LABStandard BioTools, Inc.48.51% -$0.09 $427M ADGMAdagio Medical Holdings, Inc.-- -$0.66 $20.7M -
What do Analysts Say About LAB or ADGM?
Standard BioTools, Inc. has a consensus price target of $1.65, signalling upside risk potential of 22.05%. On the other hand Adagio Medical Holdings, Inc. has an analysts' consensus of $4.00 which suggests that it could grow by 303.67%. Given that Adagio Medical Holdings, Inc. has higher upside potential than Standard BioTools, Inc., analysts believe Adagio Medical Holdings, Inc. is more attractive than Standard BioTools, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LABStandard BioTools, Inc.1 2 0 ADGMAdagio Medical Holdings, Inc.1 0 0 -
Is LAB or ADGM More Risky?
Standard BioTools, Inc. has a beta of 1.264, which suggesting that the stock is 26.42% more volatile than S&P 500. In comparison Adagio Medical Holdings, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock LAB or ADGM?
Standard BioTools, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adagio Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Standard BioTools, Inc. pays -- of its earnings as a dividend. Adagio Medical Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LAB or ADGM?
Standard BioTools, Inc. quarterly revenues are $19.6M, which are larger than Adagio Medical Holdings, Inc. quarterly revenues of --. Standard BioTools, Inc.'s net income of -$31.7M is lower than Adagio Medical Holdings, Inc.'s net income of -$10.1M. Notably, Standard BioTools, Inc.'s price-to-earnings ratio is -- while Adagio Medical Holdings, Inc.'s PE ratio is 218.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Standard BioTools, Inc. is 3.74x versus 110.91x for Adagio Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LABStandard BioTools, Inc.3.74x -- $19.6M -$31.7M ADGMAdagio Medical Holdings, Inc.110.91x 218.00x -- -$10.1M
-
Which has Higher Returns LAB or INBS?
Intelligent Bio Solutions, Inc. has a net margin of -162.05% compared to Standard BioTools, Inc.'s net margin of -269.38%. Standard BioTools, Inc.'s return on equity of -24.44% beat Intelligent Bio Solutions, Inc.'s return on equity of -255.54%.
Company Gross Margin Earnings Per Share Invested Capital LABStandard BioTools, Inc.48.51% -$0.09 $427M INBSIntelligent Bio Solutions, Inc.19.33% -$0.35 $5.4M -
What do Analysts Say About LAB or INBS?
Standard BioTools, Inc. has a consensus price target of $1.65, signalling upside risk potential of 22.05%. On the other hand Intelligent Bio Solutions, Inc. has an analysts' consensus of -- which suggests that it could grow by 1021.5%. Given that Intelligent Bio Solutions, Inc. has higher upside potential than Standard BioTools, Inc., analysts believe Intelligent Bio Solutions, Inc. is more attractive than Standard BioTools, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LABStandard BioTools, Inc.1 2 0 INBSIntelligent Bio Solutions, Inc.0 0 0 -
Is LAB or INBS More Risky?
Standard BioTools, Inc. has a beta of 1.264, which suggesting that the stock is 26.42% more volatile than S&P 500. In comparison Intelligent Bio Solutions, Inc. has a beta of 4.455, suggesting its more volatile than the S&P 500 by 345.491%.
-
Which is a Better Dividend Stock LAB or INBS?
Standard BioTools, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intelligent Bio Solutions, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Standard BioTools, Inc. pays -- of its earnings as a dividend. Intelligent Bio Solutions, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LAB or INBS?
Standard BioTools, Inc. quarterly revenues are $19.6M, which are larger than Intelligent Bio Solutions, Inc. quarterly revenues of $1.1M. Standard BioTools, Inc.'s net income of -$31.7M is lower than Intelligent Bio Solutions, Inc.'s net income of -$3M. Notably, Standard BioTools, Inc.'s price-to-earnings ratio is -- while Intelligent Bio Solutions, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Standard BioTools, Inc. is 3.74x versus 21.27x for Intelligent Bio Solutions, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LABStandard BioTools, Inc.3.74x -- $19.6M -$31.7M INBSIntelligent Bio Solutions, Inc.21.27x -- $1.1M -$3M
-
Which has Higher Returns LAB or LNSR?
LENSAR, Inc. has a net margin of -162.05% compared to Standard BioTools, Inc.'s net margin of -25.94%. Standard BioTools, Inc.'s return on equity of -24.44% beat LENSAR, Inc.'s return on equity of -1013.45%.
Company Gross Margin Earnings Per Share Invested Capital LABStandard BioTools, Inc.48.51% -$0.09 $427M LNSRLENSAR, Inc.40.56% -$0.31 -$9.2M -
What do Analysts Say About LAB or LNSR?
Standard BioTools, Inc. has a consensus price target of $1.65, signalling upside risk potential of 22.05%. On the other hand LENSAR, Inc. has an analysts' consensus of $15.00 which suggests that it could grow by 31%. Given that LENSAR, Inc. has higher upside potential than Standard BioTools, Inc., analysts believe LENSAR, Inc. is more attractive than Standard BioTools, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LABStandard BioTools, Inc.1 2 0 LNSRLENSAR, Inc.0 2 0 -
Is LAB or LNSR More Risky?
Standard BioTools, Inc. has a beta of 1.264, which suggesting that the stock is 26.42% more volatile than S&P 500. In comparison LENSAR, Inc. has a beta of 0.695, suggesting its less volatile than the S&P 500 by 30.495%.
-
Which is a Better Dividend Stock LAB or LNSR?
Standard BioTools, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LENSAR, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Standard BioTools, Inc. pays -- of its earnings as a dividend. LENSAR, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LAB or LNSR?
Standard BioTools, Inc. quarterly revenues are $19.6M, which are larger than LENSAR, Inc. quarterly revenues of $14.3M. Standard BioTools, Inc.'s net income of -$31.7M is lower than LENSAR, Inc.'s net income of -$3.7M. Notably, Standard BioTools, Inc.'s price-to-earnings ratio is -- while LENSAR, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Standard BioTools, Inc. is 3.74x versus 2.29x for LENSAR, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LABStandard BioTools, Inc.3.74x -- $19.6M -$31.7M LNSRLENSAR, Inc.2.29x -- $14.3M -$3.7M
-
Which has Higher Returns LAB or MOVE?
Movano, Inc. has a net margin of -162.05% compared to Standard BioTools, Inc.'s net margin of -5036.25%. Standard BioTools, Inc.'s return on equity of -24.44% beat Movano, Inc.'s return on equity of -410.28%.
Company Gross Margin Earnings Per Share Invested Capital LABStandard BioTools, Inc.48.51% -$0.09 $427M MOVEMovano, Inc.-250% -$4.73 $1.5M -
What do Analysts Say About LAB or MOVE?
Standard BioTools, Inc. has a consensus price target of $1.65, signalling upside risk potential of 22.05%. On the other hand Movano, Inc. has an analysts' consensus of $30.00 which suggests that it could grow by 3756.04%. Given that Movano, Inc. has higher upside potential than Standard BioTools, Inc., analysts believe Movano, Inc. is more attractive than Standard BioTools, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LABStandard BioTools, Inc.1 2 0 MOVEMovano, Inc.0 0 0 -
Is LAB or MOVE More Risky?
Standard BioTools, Inc. has a beta of 1.264, which suggesting that the stock is 26.42% more volatile than S&P 500. In comparison Movano, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock LAB or MOVE?
Standard BioTools, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Movano, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Standard BioTools, Inc. pays -- of its earnings as a dividend. Movano, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LAB or MOVE?
Standard BioTools, Inc. quarterly revenues are $19.6M, which are larger than Movano, Inc. quarterly revenues of $80K. Standard BioTools, Inc.'s net income of -$31.7M is lower than Movano, Inc.'s net income of -$4M. Notably, Standard BioTools, Inc.'s price-to-earnings ratio is -- while Movano, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Standard BioTools, Inc. is 3.74x versus 11.77x for Movano, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LABStandard BioTools, Inc.3.74x -- $19.6M -$31.7M MOVEMovano, Inc.11.77x -- $80K -$4M
-
Which has Higher Returns LAB or NPCE?
NeuroPace, Inc. has a net margin of -162.05% compared to Standard BioTools, Inc.'s net margin of -12.78%. Standard BioTools, Inc.'s return on equity of -24.44% beat NeuroPace, Inc.'s return on equity of -149.8%.
Company Gross Margin Earnings Per Share Invested Capital LABStandard BioTools, Inc.48.51% -$0.09 $427M NPCENeuroPace, Inc.77.39% -$0.11 $89.7M -
What do Analysts Say About LAB or NPCE?
Standard BioTools, Inc. has a consensus price target of $1.65, signalling upside risk potential of 22.05%. On the other hand NeuroPace, Inc. has an analysts' consensus of $19.25 which suggests that it could grow by 17.45%. Given that Standard BioTools, Inc. has higher upside potential than NeuroPace, Inc., analysts believe Standard BioTools, Inc. is more attractive than NeuroPace, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LABStandard BioTools, Inc.1 2 0 NPCENeuroPace, Inc.7 0 0 -
Is LAB or NPCE More Risky?
Standard BioTools, Inc. has a beta of 1.264, which suggesting that the stock is 26.42% more volatile than S&P 500. In comparison NeuroPace, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock LAB or NPCE?
Standard BioTools, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NeuroPace, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Standard BioTools, Inc. pays -- of its earnings as a dividend. NeuroPace, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LAB or NPCE?
Standard BioTools, Inc. quarterly revenues are $19.6M, which are smaller than NeuroPace, Inc. quarterly revenues of $27.4M. Standard BioTools, Inc.'s net income of -$31.7M is lower than NeuroPace, Inc.'s net income of -$3.5M. Notably, Standard BioTools, Inc.'s price-to-earnings ratio is -- while NeuroPace, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Standard BioTools, Inc. is 3.74x versus 5.50x for NeuroPace, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LABStandard BioTools, Inc.3.74x -- $19.6M -$31.7M NPCENeuroPace, Inc.5.50x -- $27.4M -$3.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
69
RGC alert for Jan 7
Regencell Bioscience Holdings Ltd. [RGC] is up 58.95% over the past day.
Buy
69
WDC alert for Jan 7
Western Digital Corp. [WDC] is down 8.88% over the past day.
Buy
75
DRUG alert for Jan 7
Bright Minds Biosciences, Inc. [DRUG] is up 2.99% over the past day.
